Why So Many Women Stay in Pain
Post-mastectomy pain syndrome affects up to 60% of women who undergo breast cancer surgery, making it one of the most common complications of a very common procedure. The pain can feel like burning, stabbing, tightness, or numbness — often in the chest wall, armpit, or arm.
For years, doctors have tried to classify it as either neuropathic (nerve pain, from surgical damage to nerve fibers) or nociceptive (tissue pain, from ongoing inflammation or structural changes). The classification matters because these two types of pain respond to different treatments.
One Size Does Not Fit All
The old model said: figure out whether it's nerve pain or tissue pain, and treat accordingly.
But here's what this study found: a large slice of patients — about one in three — don't fit neatly into either category. They have both types at once. This "mixed pain" phenotype has been discussed in theory but is poorly defined in practice. And if a doctor treats only one type, the other keeps hurting.
What Drives Mixed Pain?
Think of it like a fire that started in one room and spread to two others. If you only put out the original fire, the other rooms keep burning.
In women with PMPS, multiple things can go wrong at the same time. Surgery cuts nerves, creating neuropathic (nerve-related) pain signals. Tissue scarring or inflammation adds nociceptive (tissue-damage) pain on top. Radiation therapy — used in many breast cancer cases — can damage both nerves and surrounding tissue, adding yet another layer. When these sources overlap, treating just one of them leaves the others untouched.
Who Was Studied
Researchers at a tertiary cancer pain clinic (a specialized clinic for complex, treatment-resistant cases) reviewed data from 120 women with refractory PMPS (pain that hadn't responded to standard treatment) who were seen between January 2022 and September 2025. The women had a mean age of about 58 years. Clinicians classified each patient's pain type using a structured clinical assessment.
Of the 120 women, 40.8% had nociceptive pain, 25% had neuropathic pain, and 34.2% had mixed pain. Pain intensity and how much it interfered with daily life were high across all three groups — and similar between groups, meaning mixed pain wasn't necessarily "worse" in severity, just different in character.
Two factors stood out as strongly linked to having mixed pain. Women with two or more distinct sources of pain — for example, both a surgical scar and lymphedema — were nearly 50 times more likely to have mixed pain than those with a single source. Women whose pain was attributed to radiation therapy were about six times more likely to have mixed pain.
This does not mean that radiation therapy should be avoided — its life-saving benefits are well established — but it does mean that women who received radiation may need extra attention for pain management.
That's Not the Whole Story
Pain severity scores were similar across all three groups, which surprised researchers. It suggests that the type of pain, not just how intense it feels, determines whether standard treatments work. A patient with moderate mixed pain may struggle more than a patient with severe but straightforward neuropathic pain — because the tools available are better matched to single-type pain.
What This Means in the Bigger Picture
The researchers frame this as a hypothesis-generating study — meaning it raises important questions rather than providing final answers. Still, it fits into a growing body of evidence that a mechanism-based approach to pain (figuring out what's causing it at a biological level) works better than a one-size-fits-all approach.
If you are living with persistent pain after breast cancer surgery, this research suggests it may be worth asking your doctor whether your pain has been assessed for mixed features. Standard pain questionnaires may not capture the full picture. A referral to a pain specialist — particularly one with experience in cancer-related pain — could lead to a more tailored treatment plan.
Honest Limitations
This study included only women already referred to a specialist clinic, meaning the results may not apply to all women with PMPS. The sample was also relatively small, and the study design makes it impossible to draw firm conclusions about cause and effect. The statistical models used to identify risk factors have limitations that the authors themselves acknowledge.
The findings point toward a need for clinical guidelines that formally recognize mixed pain as a distinct category in post-mastectomy care. Future research should test whether identifying mixed pain early — before patients become refractory cases — allows for better treatment outcomes. Mechanism-based pain assessment tools are still being developed and validated, and broader adoption could change how this condition is managed in the coming years.